Related Experiment Video
Updated: Jun 23, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.6K
Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization
Alaa Elmazny1, Sherif M Hamdy1, Maged Abdel-Naseer1
1Neurology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Journal of Pain Research
|March 27, 2020
Summary
Interferon-beta (IFN-β) treatment for multiple sclerosis (MS) can worsen existing headaches or cause new ones. The risk of headaches is higher with intramuscular (IM) INF-β-1a and 44 μg subcutaneous (SC) INF-β-1a compared to 22 μg SC INF-β-1a.
Area of Science:
- Neurology
- Pharmacology
Background:
- Interferon-beta (IFN-β) is a common treatment for multiple sclerosis (MS).
- Headaches are a frequent adverse effect of IFN-β therapy, impacting patient quality of life.
- Understanding headache patterns in response to IFN-β is crucial for MS management.
Purpose of the Study:
- To investigate the frequency, patterns, and characteristics of headaches in patients with relapsing-remitting multiple sclerosis (RRMS) treated with IFN-β.
- To analyze the temporal relationship between IFN-β treatment initiation and headache onset or exacerbation.
- To identify risk factors associated with IFN-β-induced headaches.
Main Methods:
- Prospective, longitudinal study with 1-year follow-up of 796 RRMS patients treated with IFN-β.
- Headache diagnosis based on the International Classification of Headache Disorders (ICHD-3).
- Data collected via interviewer-administered Arabic questionnaire assessing headache characteristics and treatment relationship.
Main Results:
- 356 patients developed new (de novo) headaches, and 276 had pre-existing headaches that worsened.
- Among those with pre-existing headaches, 55 experienced worsening after starting IFN-β.
- Increased headache risk observed with intramuscular INF-β-1a (OR 6.51) and 44 μg subcutaneous INF-β-1a (OR 5.44) compared to 22 μg SC INF-β-1a.
Conclusions:
- IFN-β therapy can induce primary headaches and exacerbate pre-existing headaches in MS patients.
- Treatment with intramuscular INF-β-1a and higher-dose subcutaneous INF-β-1a (44 μg) is associated with a greater risk of headaches.
More Related Videos
Related Concept Videos
01:24Bacterial Meningitis
Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:19Encephalitis l: Introduction
Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...